Atossa Therapeutics
Providing innovative treatments for pre-cancerous breast conditions and early-stage breast cancer.
Providing innovative treatments for pre-cancerous breast conditions and early-stage breast cancer.
Atossa Therapeutics is a clinical-stage biopharmaceutical company established in 2009 with a mission to provide innovative treatments for pre-cancerous breast conditions and early-stage breast cancer. Their slogan, "Providing innovative treatments for pre-cancerous breast conditions and early-stage breast cancer," reflects their dedication to addressing critical unmet medical needs in the field of Biotechnology and Health Care. The company recently secured a notable $25.20M in Post-IPO Equity investment on 01 January 2021, showcasing investor confidence in their research and development efforts. As a potential investment opportunity, Atossa Therapeutics presents an intriguing proposition within the biopharmaceutical sector. Their focus on addressing breast cancer and related conditions aligns with market needs, and the recent investment reaffirms investor interest and support in the company's initiatives. Therefore, this company warrants a closer examination for venture capital firms seeking exposure to innovative advancements in the healthcare industry.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $25.20M | - | 01 Jan 2021 | |
| Post-IPO Equity | $25.00M | 1 |
|
28 May 2015 |
| Post-IPO Equity | $1.00M | - | 11 Apr 2013 | |
| Venture Round | $6.60M | - | 27 Jun 2011 | |
| Venture Round | Unknown | 1 |
|
01 Jan 2011 |
No recent news or press coverage available for Atossa Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
